Status:

UNKNOWN

Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI

Lead Sponsor:

Lady Davis Institute

Conditions:

Acneiform Eruptions

Cancer, Treatment-Related

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Tyrosine Kinase inhibitors (TKIs) have become standard of care in patients with EGFR mutations in non-small cell lung cancer and other EGFR-mutated cancers. However, TKIs are well-known to cause cutan...

Detailed Description

Background and Study Aims: Tyrosine Kinase inhibitors (TKIs) have become standard of care in patients with EGFR mutations in non-small cell lung cancer and other EGFR-mutated cancers. However, TKIs a...

Eligibility Criteria

Inclusion

  • Participant must be ≥18 years of age, able to understand the study procedures, and agrees to participate in the study by providing written informed consent
  • Participant has histologically- or pathologically-confirmed cancer with a known sensitizing EGFR mutation.
  • Participants must have started EGFR-TKI treatment, and subsequently had an acneiform eruption rated moderate or severe per the Leeds scale.
  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  • Participant has a life expectancy of at least 3 months.
  • Premenopausal participants must use highly effective method of contraception. Female participants are neither pregnant nor breastfeeding

Exclusion

  • Absolute contraindications: pregnancy, breastfeeding, drug allergy
  • Relative contraindications:
  • moderate to severe hypercholesterolemia (total cholesterol \>7.8 mmol/L)
  • hypertriglyceridemia (TG \>2.55 mmol/L)
  • significant hepatic dysfunction (AST \> 55IU/L, ALT \> 94 IU/L)
  • suicidal ideation, pseudotumor cerebri
  • refractory nausea or vomiting
  • GI pathology that would prevent absorption of oral therapy.

Key Trial Info

Start Date :

September 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2022

Estimated Enrollment :

98 Patients enrolled

Trial Details

Trial ID

NCT04864717

Start Date

September 1 2021

End Date

December 1 2022

Last Update

September 8 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Jewish General Hospital

Montreal, Quebec, Canada, H3T 1E2